Colonisation endpoints in Streptococcus pneumoniae vaccine trials

Vaccine

Volumn 32, Issue 1, 2013, Pages 153-158

  Auranen, Kari ^a   Rinta Kokko, Hanna ^a   Goldblatt, David ^b   Nohynek, Hanna ^a   O'Brien, Katherine L ^c   Satzke, Catherine ^d,e   Simell, Birgit ^a   Tanskanen, Antti ^a   Käyhty, Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Nasopharyngeal colonisation; Pneumococcus; Trial endpoint; Vaccine efficacy

Indexed keywords

PNEUMOCOCCUS VACCINE;

BACTERIAL COLONIZATION; CROSS-SECTIONAL STUDY; DRUG EFFICACY; HUMAN; IMMUNIZATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

COMBINED VACCINE EFFICACY AGAINST ACQUISITION AND DURATION OF COLONISATION; NASOPHARYNGEAL COLONISATION; NON-VACCINE (SERO)TYPE(S); NVT; ODDS RATIO; OR; PCV; PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS; TRIAL ENDPOINT; VACCINE (SERO)TYPE(S); VACCINE EFFICACY; VACCINE EFFICACY AGAINST ACQUISITION OF COLONISATION; VACCINE EFFICACY AGAINST COLONISATION; VE(ACQ); VE(COL); VE(T); VT;

CARRIER STATE; CROSS-SECTIONAL STUDIES; HUMANS; NASOPHARYNX; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; STREPTOCOCCUS PNEUMONIAE;

EID: 84891909675     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.061     Document Type: Review

References (22)

1. Barbour M.L., Mayon-White R.T., Coles C., Crook D.W., Moxon E.R. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995, 171(1):93-98.
2. Maiden M.C., Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359(9320):1829-1831. UK Meningococcal Carriage Group.
3. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180(4):1171-1176.
4. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326(7385):365-366.
5. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(9546):1495-1502.
6. Centers for Disease Control and Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54(36):893-897.
7. Simell B., Auranen K., Käyhty H., Dagan R., O'Brien K. The fundamental link between pneumococcal carriage and disease. Exp Rev Vaccines 2012, 11(7):841-855.
8. Jódar L., Butler J., Carlone G., Dagan R., Goldblatt D., Käyhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21:3263-3272.
9. Siber G., Chang I., Baker S., Fernsten P., O'Brien K.L., Santosham M., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007, 25:3816-3826.
10. Rinta-Kokko H., Dagan R., Givon-Lavi N., Auranen K. Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine 2009, 27(29):3831-3837.
11. Auranen K., Rinta-Kokko H., Halloran M.E. Estimating strain-specific and overall vaccine efficacy of polyvalent vaccines against pathogens with recurrent dynamics from a cross-sectional study. Biometrics 2013, 69(1):235-244.
12. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination. An alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303(10):549-552.
13. Gilbert P.B. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. Stat Med 2001, 20(2):263-279.
14. Auranen K., Rinta-Kokko H., Goldblatt D., Nohynek H., O'Brien K.L., Satzke C., et al. Design questions for Streptococcus pneumoniae vaccine trials with a colonisation endpoint. Vaccine 2013, 32(1):159-164.
15. Halloran M.E., Longini I.M., Struchiner C. Design and Analysis of Vaccine Studies 2010, Springer, New York.
16. Becker N., Starczak D. The effect of random vaccine response on the vaccination coverage required to prevent epidemics. Math Biosci 1998, 154(2):117-135.
17. Dagan R., Muallem M., Melamed R., Leroy O., Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997, 16(11):1060-1064.
18. Russell F.M., Licciardi P.V., Balloch A., Biaukula V., Tikoduadua L., Carapetis J.R., et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 2010, 28(18):3086-3094.
19. Scott J.A., Ojal J., Ashton L., Muhoro A., Burbidge P., Goldblatt D. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis 2011, 53(7):663-670.
20. Dagan R., Givon-Lavi N., Fraser D., Lipsitch M., Siber G.R., Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 2005, 192(3):367-376.
21. O'Brien K.L., Millar E.V., Zell E.R., Bronsdon M., Weatherholz R., Reid R., et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007, 196(8):1211-1220.
22. Omori R., Cowling B.J., Nishiura H. How is vaccine effectiveness scaled by the transmission dynamics of interacting pathogen strains with cross-protective immunity?. PLoS One 2012, 7(11):e50751. 10.1371/journal.pone.0050751.